Fortress Biotech, Inc. (FBIO)Healthcare | Biotechnology | Bay Harbor Islands, United States | NasdaqCM
3.30 USD
After hours: 3.31 +0.01 (0.303%) ⇧ (July 13, 2026, 7:41 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:44 a.m. EDT
Fortress Biotech presents a stark case of a business trapped in a death spiral, making it a dangerous hold for any investor. The company is currently paying deferred preferred dividends, a critical red flag indicating severe liquidity distress and an inability to meet basic obligations without external intervention. Fundamentally, the stock has suffered a catastrophic 95.68% decline over the last nine years, with four consecutive years of negative annual returns, signaling that the market has permanently repriced the asset due to deteriorating prospects. While the balance sheet shows a low debt-to-equity ratio, this is misleading in a biotech context where cash burn is the primary killer; the operating cash flow is insufficient to sustain operations without capital raises, which dilute shareholders. The options market confirms this pessimism, with traders aggressively buying deep out-of-the-money puts, betting on further collapse rather than recovery. Despite a theoretical P/E under two, this metric is meaningless given the negative forward earnings and the reality that the company is effectively insolvent in terms of growth potential. There is no catalyst strong enough to justify a long position here; the only logical trade is a short, though the risk of a distressed liquidation or reverse split complicates execution. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.134981 |
| AutoARIMA | 0.135271 |
| AutoETS | 0.139122 |
| AutoTheta | 0.258675 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 8.19 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.354 |
| Excess Kurtosis | -0.53 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 26.499 |
| Revenue per Share | 2.268 |
| Market Cap | 109,622,936 |
| Trailing P/E | 1.02 |
| Forward P/E | -1.88 |
| Beta | 1.21 |
| Profit Margins | 193.12% |
| Website | https://www.fortressbiotech.com |
As of July 11, 2026, 3:44 a.m. EDT: Speculators are overwhelmingly positioning for downside protection, evidenced by massive open interest in out-of-the-money puts compared to calls across all expirations. Implied volatility for puts is significantly elevated relative to calls, indicating a market expectation of further price weakness rather than a rally. The heavy concentration of put volume at strikes far above the current price suggests a fear of a gap-down event or continued structural decline.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.6836735 |
| Address1 | 1,111 Kane Concourse |
| Address2 | Suite 301 |
| All Time High | 190.5 |
| All Time Low | 1.24 |
| Ask | 4.26 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 567,910 |
| Average Daily Volume3 Month | 433,331 |
| Average Volume | 433,331 |
| Average Volume10Days | 567,910 |
| Beta | 1.21 |
| Bid | 2.46 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 4.888 |
| City | Bay Harbor Islands |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.3 |
| Current Ratio | 2.858 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.46 |
| Day Low | 3.295 |
| Debt To Equity | 26.499 |
| Display Name | Fortress Biotech |
| Earnings Timestamp End | 1,755,115,200 |
| Earnings Timestamp Start | 1,755,115,200 |
| Ebitda | -50,954,000 |
| Ebitda Margins | -0.77015 |
| Enterprise To Ebitda | 1.029 |
| Enterprise To Revenue | -0.792 |
| Enterprise Value | -52,422,064 |
| Eps Forward | -1.76 |
| Eps Trailing Twelve Months | 3.23 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.7344 |
| Fifty Day Average Change | 0.5655999 |
| Fifty Day Average Change Percent | 0.20684607 |
| Fifty Two Week Change Percent | 68.36735 |
| Fifty Two Week High | 4.53 |
| Fifty Two Week High Change | -1.2300003 |
| Fifty Two Week High Change Percent | -0.27152324 |
| Fifty Two Week Low | 1.77 |
| Fifty Two Week Low Change | 1.53 |
| Fifty Two Week Low Change Percent | 0.86440676 |
| Fifty Two Week Range | 1.77 - 4.53 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,321,540,200,000 |
| Float Shares | 23,090,909 |
| Forward Eps | -1.76 |
| Forward P E | -1.875 |
| Free Cashflow | 14,971,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 78 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.53363997 |
| Gross Profits | 35,306,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.22791 |
| Held Percent Institutions | 0.24759 |
| Implied Shares Outstanding | 33,219,072 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,696,896,000 |
| Last Split Factor | 1:15 |
| Long Business Summary | Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. |
| Long Name | Fortress Biotech, Inc. |
| Market | us_market |
| Market Cap | 109,622,936 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_61731337 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 119,198,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 109,456,842 |
| Number Of Analyst Opinions | 2 |
| Open | 3.31 |
| Operating Cashflow | 157,636,992 |
| Operating Margins | -0.48254 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 781 652 4500 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.30303 |
| Post Market Price | 3.31 |
| Post Market Time | 1,783,986,112 |
| Previous Close | 3.3 |
| Price Hint | 4 |
| Price To Book | 0.67512274 |
| Price To Sales Trailing12 Months | 1.6569117 |
| Profit Margins | 1.9312301 |
| Quick Ratio | 2.721 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 3.46 |
| Regular Market Day Low | 3.295 |
| Regular Market Day Range | 3.295 - 3.46 |
| Regular Market Open | 3.31 |
| Regular Market Previous Close | 3.3 |
| Regular Market Price | 3.3 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 861,958 |
| Return On Assets | -0.13002 |
| Return On Equity | 1.098 |
| Revenue Growth | 0.221 |
| Revenue Per Share | 2.268 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 33,219,072 |
| Shares Percent Shares Out | 0.1597 |
| Shares Short | 5,305,659 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 5,090,428 |
| Short Name | Fortress Biotech, Inc. |
| Short Percent Of Float | 0.2069 |
| Short Ratio | 9.63 |
| Source Interval | 15 |
| State | FL |
| Symbol | FBIO |
| Target High Price | 17.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 11.0 |
| Total Cash | 255,840,992 |
| Total Cash Per Share | 7.702 |
| Total Debt | 53,627,000 |
| Total Revenue | 66,161,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 3.23 |
| Trailing P E | 1.0216718 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.9692 |
| Two Hundred Day Average Change | 0.33080006 |
| Two Hundred Day Average Change Percent | 0.111410506 |
| Type Disp | Equity |
| Volume | 861,958 |
| Website | https://www.fortressbiotech.com |
| Zip | 33,154 |